Localized Adult Ewing Sarcoma: Favorable Outcomes with Alternating Vincristine, Doxorubicin, Cyclophosphamide, and Ifosfamide, Etoposide (VDC/IE)‐Based Multimodality Therapy

Background In children with localized Ewing sarcoma (ES), addition of ifosfamide and etoposide to cyclophosphamide, doxorubicin, and vincristine (VDC/IE) improved 5‐year overall survival (OS) to 70%–80%. Prior to delivery of VDC/IE in adults, 5‐year OS was

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2017-10, Vol.22 (10), p.1265-1270
Hauptverfasser:	Pretz, Jennifer L., Barysauskas, Constance M., George, Suzanne, Hornick, Jason L., Raut, Chandrajit. P., Chen, Yen-Lin E., Marcus, Karen J., Choy, Edwin, Hornicek, Francis, Ready, John E., DeLaney, Thomas F., Baldini, Elizabeth H.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Disease-Free Survival Ewing sarcoma Female Humans Localized Male Middle Aged Pelvis Radiotherapy Sarcoma, Ewing - drug therapy Sarcoma, Ewing - pathology Sarcomas Surgery Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background In children with localized Ewing sarcoma (ES), addition of ifosfamide and etoposide to cyclophosphamide, doxorubicin, and vincristine (VDC/IE) improved 5‐year overall survival (OS) to 70%–80%. Prior to delivery of VDC/IE in adults, 5‐year OS was
ISSN:	1083-7159 1549-490X
DOI:	10.1634/theoncologist.2016-0463